# US 8,278,296 B2 · Manipulation of brain CDP-diacylglycerol and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,296 B2
- Document ID: US8278296B2
- Status: Granted
- Kind: B2
- Application number: 12/804,534
- Filed: 2010-07-23
- Published: 2010-12-09
- Granted: 2012-10-02
- Earliest claimed: 2006-08-10
- Inventors: Ashiwel S. Undieh
- Web page: https://patentgrep.com/patent/US8278296B2

## CPC

- G01N 33/5058: {Neurological cells}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/24: Antidepressants
- G01N 2800/304: Mood disorders, e.g. bipolar, depression
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.

## Claims

### Claim 1

A method of diagnosing a depressive disorder in a subject, comprising:
determining a basal CDP-diacylglycerol/inositol phosphate index that is the ratio of a level of CDP-diacylglycerol to a level of inositolphosphatein the subject; and comparing the basal CDP-diacylglycerol/inositol phosphate index to a control CDP-diacylglycerol/inositol phosphate index, wherein a lower basal CDP-diacylglycerol/inositol phosphate index indicates the subject has a depressive disorder, wherein the depressive disorder is major depression, unipolar depression, bipolar depression, reactive depression, endogenous depression, or dysthymic disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the diagnosis is predictive of the onset of the depressive disorder.

### Claim 3 (depends on 1)

The method of claim 1, wherein the diagnosis is predictive of severity of the depressive disorder, wherein a determined CDP-diacylglycerol/inositol phosphate index value that is much lower than the control index suggests a more severe depressive disorder.

### Claim 4 (depends on 1)

The method of claim 1, wherein the diagnosis is predictive of remission of the depressive disorder, wherein a determined CDP-diacylglycerol/inositol phosphate index value that is regressing towards the control index suggests a remitting depressive disorder.

### Claim 5 (depends on 4)

The method of claim 4, wherein the remission is spontaneous.

### Claim 6 (depends on 4)

The method of claim 4, wherein the remission is effected by therapy.

### Claim 7 (depends on 6)

The method of claim 6, wherein the therapy comprises an antidepressant drug.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antidepressant drug is tricyclic antidepressant, selective serotonin reuptake inhibitor, atypical antidepressant or derivatives or analogs thereof, or a synthetic antidepressant compound that increases production of cdp-diacylglycerol in a depression-relevant brain tissue or blood platelets upon contact therewith.
